Literature DB >> 26750128

Nitrosoureas in the Management of Malignant Gliomas.

Alba A Brandes1, Marco Bartolotti2, Alicia Tosoni2, Enrico Franceschi2.   

Abstract

Nitrosoureas represent one of the most active classes of agents in the treatment of high-grade gliomas and glioblastoma. In clinical practice, the most commonly used compounds are lomustine (either alone or in combination with procarbazine and vincristine), carmustine, and fotemustine. Given their toxicity profile and subsequent to the introduction of temozolomide in clinical practice, most of these agents were moved to the recurrent setting. This review focuses on the role of the nitrosoureas currently used in clinical practice for the treatment of malignant gliomas.

Entities:  

Keywords:  Anaplastic; Chemotherapy; Glioblastoma; Glioma; Nitrosoureas

Mesh：

Substances：

Year:  2016        PMID： 26750128     DOI： 10.1007/s11910-015-0611-8

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN： 1528-4042            Impact factor:   5.081


  31 in total

1.  Nitrosourea chemotherapy for primary malignant gliomas.

Authors:  V A Levin; C B Wilson
Journal:  Cancer Treat Rep       Date:  1976-06

2.  Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma.

Authors:  Wolfgang Wick; Vinay K Puduvalli; Marc C Chamberlain; Martin J van den Bent; Antoine F Carpentier; Lawrence M Cher; Warren Mason; Michael Weller; Shengyan Hong; Luna Musib; Astra M Liepa; Donald E Thornton; Howard A Fine
Journal:  J Clin Oncol       Date:  2010-02-01       Impact factor: 44.544

3.  BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors.

Authors:  Thomas Reithmeier; Erika Graf; Tobias Piroth; Michael Trippel; Marcus O Pinsker; Guido Nikkhah
Journal:  BMC Cancer       Date:  2010-02-02       Impact factor: 4.430

4.  Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.

Authors:  Gregory Cairncross; Meihua Wang; Edward Shaw; Robert Jenkins; David Brachman; Jan Buckner; Karen Fink; Luis Souhami; Normand Laperriere; Walter Curran; Minesh Mehta
Journal:  J Clin Oncol       Date:  2012-10-15       Impact factor: 44.544

5.  High-dose BCNU and autologous progenitor cell transplantation given with intra-arterial cisplatinum and simultaneous radiotherapy in the treatment of high-grade gliomas: benefit for selected patients.

Authors:  O A Fernández-Hidalgo; V Vanaclocha; J M Vieitez; J J Aristu; J Rebollo; A Gúrpide; J M Aramendía; R Moreno-Palanques; S Martín-Algarra; M L Subirá; A Brugarolas
Journal:  Bone Marrow Transplant       Date:  1996-07       Impact factor: 5.483

6.  How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial.

Authors:  A A Brandes; A Tosoni; P Amistà; L Nicolardi; D Grosso; F Berti; M Ermani
Journal:  Neurology       Date:  2004-10-12       Impact factor: 9.910

7.  Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery.

Authors:  M D Walker; S B Green; D P Byar; E Alexander; U Batzdorf; W H Brooks; W E Hunt; C S MacCarty; M S Mahaley; J Mealey; G Owens; J Ransohoff; J T Robertson; W R Shapiro; K R Smith; C B Wilson; T A Strike
Journal:  N Engl J Med       Date:  1980-12-04       Impact factor: 91.245

8.  Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide.

Authors:  Wolfgang Wick; Patrick Roth; Christian Hartmann; Peter Hau; Makoto Nakamura; Florian Stockhammer; Michael C Sabel; Antje Wick; Susanne Koeppen; Ralf Ketter; Peter Vajkoczy; Ilker Eyupoglu; Rolf Kalff; Torsten Pietsch; Caroline Happold; Norbert Galldiks; Friederike Schmidt-Graf; Michael Bamberg; Guido Reifenberger; Michael Platten; Andreas von Deimling; Christoph Meisner; Benedikt Wiestler; Michael Weller
Journal:  Neuro Oncol       Date:  2016-07-01       Impact factor: 12.300

9.  Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.

Authors:  Tracy T Batchelor; Paul Mulholland; Bart Neyns; L Burt Nabors; Mario Campone; Antje Wick; Warren Mason; Tom Mikkelsen; Surasak Phuphanich; Lynn S Ashby; John Degroot; Rao Gattamaneni; Lawrence Cher; Mark Rosenthal; Franz Payer; Juliane M Jürgensmeier; Rakesh K Jain; A Gregory Sorensen; John Xu; Qi Liu; Martin van den Bent
Journal:  J Clin Oncol       Date:  2013-08-12       Impact factor: 44.544

10.  IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.

Authors:  Martin J van den Bent; Hendrikus J Dubbink; Yannick Marie; Alba A Brandes; Martin J B Taphoorn; Pieter Wesseling; Marc Frenay; Cees C Tijssen; Denis Lacombe; Ahmed Idbaih; Ronald van Marion; Johan M Kros; Winand N M Dinjens; Thierry Gorlia; Marc Sanson
Journal:  Clin Cancer Res       Date:  2010-02-16       Impact factor: 13.801
View more
  15 in total

Review 1.  Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.

Authors:  Patrick Y Wen; Michael Weller; Eudocia Quant Lee; Brian M Alexander; Jill S Barnholtz-Sloan; Floris P Barthel; Tracy T Batchelor; Ranjit S Bindra; Susan M Chang; E Antonio Chiocca; Timothy F Cloughesy; John F DeGroot; Evanthia Galanis; Mark R Gilbert; Monika E Hegi; Craig Horbinski; Raymond Y Huang; Andrew B Lassman; Emilie Le Rhun; Michael Lim; Minesh P Mehta; Ingo K Mellinghoff; Giuseppe Minniti; David Nathanson; Michael Platten; Matthias Preusser; Patrick Roth; Marc Sanson; David Schiff; Susan C Short; Martin J B Taphoorn; Joerg-Christian Tonn; Jonathan Tsang; Roel G W Verhaak; Andreas von Deimling; Wolfgang Wick; Gelareh Zadeh; David A Reardon; Kenneth D Aldape; Martin J van den Bent
Journal:  Neuro Oncol       Date:  2020-08-17       Impact factor: 12.300

2.  A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma.

Authors:  Alba A Brandes; Miguel Gil-Gil; Frank Saran; Antoine F Carpentier; Anna K Nowak; Warren Mason; Vittorina Zagonel; François Dubois; Gaetano Finocchiaro; George Fountzilas; Dana Michaela Cernea; Oliver Chinot; Rodica Anghel; Francois Ghiringhelli; Patrick Beauchesne; Giuseppe Lombardi; Enrico Franceschi; Martina Makrutzki; Chiedzo Mpofu; Hans-Joerg Urban; Josef Pichler
Journal:  Oncologist       Date:  2018-09-28

3.  Bevacizumab as a last-line treatment for glioblastoma following failure of radiotherapy, temozolomide and lomustine.

Authors:  Katharina J Wenger; Marlies Wagner; Se-Jong You; Kea Franz; Patrick N Harter; Michael C Burger; Martin Voss; Michael W Ronellenfitsch; Emmanouil Fokas; Joachim P Steinbach; Oliver Bähr
Journal:  Oncol Lett       Date:  2017-05-25       Impact factor: 2.967

4.  Third-line therapy in recurrent glioblastoma: is it another chance for bevacizumab?

Authors:  Enrico Franceschi; Giuseppe Lamberti; Alexandro Paccapelo; Monica Di Battista; Giovenzio Genestreti; Santino Minichillo; Antonella Mura; Stefania Bartolini; Raffaele Agati; Alba A Brandes
Journal:  J Neurooncol       Date:  2018-04-18       Impact factor: 4.130

5.  Inhibition of histone deacetylases sensitizes glioblastoma cells to lomustine.

Authors:  Mikkel Staberg; Signe Regner Michaelsen; Rikke Darling Rasmussen; Mette Villingshøj; Hans Skovgaard Poulsen; Petra Hamerlik
Journal:  Cell Oncol (Dordr)       Date:  2016-10-20       Impact factor: 6.730

6.  Does interventional MRI-guided brain cryotherapy cause a blood-brain barrier disruption? Radiological analysis and perspectives.

Authors:  Charles-Henry Mallereau; Seyyid Baloglu; Salvatore Chibbaro; Vincent Noblet; Julien Todeschi; Georges Noel; Afshin Gangi; Michel De Mathelin; François Proust; Helène Cebula
Journal:  Neurosurg Rev       Date:  2021-10-06       Impact factor: 3.042

Review 7.  Therapeutic strategies of glioblastoma (GBM): The current advances in the molecular targets and bioactive small molecule compounds.

Authors:  Hui Liu; Weimin Qiu; Tianyu Sun; Lei Wang; Chenxi Du; Yanyu Hu; Wenyuan Liu; Feng Feng; Yao Chen; Haopeng Sun
Journal:  Acta Pharm Sin B       Date:  2021-12-31       Impact factor: 14.903

Review 8.  Relapsed Glioblastoma: Treatment Strategies for Initial and Subsequent Recurrences.

Authors:  Alicia Tosoni; Enrico Franceschi; Rosalba Poggi; Alba A Brandes
Journal:  Curr Treat Options Oncol       Date:  2016-09

9.  Biweekly fotemustine schedule for recurrent glioblastoma in the elderly: activity and toxicity assessment of a multicenter study.

Authors:  Raffaele Addeo; Giuseppe Lamberti; Giorgia Simonetti; Patrizia Iodice; Alfredo Marinelli; Liliana Montella; Salvatore Cappabianca; Paola Gaviani; Michele Caraglia; Salvatore Del Prete; Antonio Silvani
Journal:  CNS Oncol       Date:  2019-07-10

Review 10.  Research progress of anti-glioma chemotherapeutic drugs (Review).

Authors:  Yi-Shu Zhou; Wei Wang; Na Chen; Li-Cui Wang; Jin-Bai Huang
Journal:  Oncol Rep       Date:  2022-04-01       Impact factor: 3.906
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.